The China National Medical Products Administration has accepted BeiGene’s (NASDAQ:BGNE)
supplemental new drug application (sNDA) for anti-PD-1 antibody
tislelizumab in combination with chemotherapy for first-line treatment
of patients with advanced non-squamous non-small cell lung cancer
(NSCLC).
Tislelizumab is approved in China as a treatment
for patients with classical Hodgkin’s lymphoma and with locally advanced
or metastatic urothelial carcinoma.
Tislelizumab is not approved for use outside of China.
https://seekingalpha.com/news/3584426-beigene-application-for-tislelizumab-accepted-in-china-for-lung-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.